Gastric acid resistance testing evaluates whether dietary supplements—particularly probiotics, enteric-coated tablets, and delayed-release formulations—can withstand the harsh acidic environment of the human stomach before delivering their active ingredients to the intended site of absorption. This testing is essential for substantiating targeted-release claims, verifying probiotic survival through gastric transit, and supporting regulatory compliance across major markets. Accredited third-party laboratories perform these evaluations using simulated gastric fluid and internationally recognized standards from USP, ISO, GB, and national pharmacopeial methods.
Technical Overview
The human stomach maintains one of the most aggressive chemical environments in the body, with fasting-state pH values typically ranging from 1.5 to 3.5 and gastric residence times of approximately 0.5 to 2 hours, extending up to 4 hours in the fed state. For many dietary supplement categories, this environment represents a critical barrier that determines whether a product delivers its intended function. Live probiotic microorganisms may be inactivated, acid-labile compounds such as enzymes and certain botanical actives may degrade, and improperly coated dosage forms may release their contents prematurely in the stomach rather than in the intestine.
Gastric acid resistance testing, also referred to as acid tolerance testing or gastric stability testing, is an in vitro laboratory evaluation that reproduces the physiological conditions of the stomach using simulated gastric fluid (SGF). The test quantifies how well a finished supplement product withstands acid exposure through measurable indicators such as probiotic survival rate, disintegration behavior, dissolution profile, and active ingredient retention. The results provide objective, reproducible evidence of product performance and are widely used for formulation development, quality control, and marketing claim substantiation.
Key performance questions addressed by this testing include:
- Do enteric-coated products remain physically intact at pH 1.2 to 3.0 while dissolving completely at intestinal pH 6.5 to 7.5?
- Do probiotic cells maintain viability during simulated gastric transit, and what is the log reduction in colony-forming units?
- Are acid-sensitive active ingredients adequately protected by encapsulation, coating, or matrix technologies?
- Does the product perform consistently across production batches and throughout its declared shelf life?
The testing framework draws on established compendial and national standards, including USP General Chapter 2040 (Disintegration and Dissolution of Dietary Supplements), USP General Chapter 711 (Dissolution), USP General Chapter 701 (Disintegration), the harmonized INFOGEST static in vitro digestion protocol, ISO 19344 for probiotic enumeration, and applicable GB standards such as GB 4789.35 for lactic acid bacteria enumeration. Together, these methods provide a technically defensible basis for evaluating acid resistance claims.
Testing Samples
Probiotic Products
Capsules, tablets, sachets, powders, and solid beverages containing live microorganisms such as Lactobacillus, Bifidobacterium, and Streptococcus species. Both conventional formulations and advanced formats such as microencapsulated, enteric-coated, or spore-forming cultures are tested to quantify viable cell recovery after acid exposure.
Enteric-Coated Tablets and Capsules
Delayed-release solid dosage forms designed to bypass gastric dissolution entirely, including enteric-coated tablets, hard capsules with acid-resistant shells, and softgels carrying marine oils, garlic oil, or other actives intended for intestinal release.
Acid-Labile Functional Ingredients
Products containing compounds with demonstrated sensitivity to low pH, including digestive enzymes, bioactive peptides, certain polyphenols, and standardized botanical extracts, where premature gastric release significantly reduces bioavailability.
Advanced Delivery Systems
Microcapsules, liposomes, alginate beads, and double-emulsion systems engineered for gastric protection, requiring verification that the protective structure functions as designed under acidic conditions.
Conventional Immediate-Release Supplements
Standard tablets, capsules, and softgels without enteric protection, tested to characterize release behavior, coating integrity, and the stability of actives during gastric residence.
For a robust evaluation, laboratories typically recommend submitting at least three production batches in final commercial packaging, with sufficient quantity to perform replicate testing plus retention samples. Products approaching expiration or stored under stressed conditions may be tested to support shelf-life performance claims.
Testing Items
Depending on the product type and the claims to be supported, a gastric acid resistance evaluation may include the following test items:
- Probiotic acid tolerance: viable cell count before and after acid exposure, expressed as survival rate percentage or log reduction (log CFU/g).
- Disintegration time in simulated gastric fluid: measurement of the period during which the dosage form remains intact at pH 1.2 to 2.0.
- Two-stage disintegration and dissolution: sequential testing in acid medium followed by intestinal buffer to confirm site-specific release.
- Dissolution profile in acid medium: quantification of active ingredient released during the gastric stage, typically required to remain below 10 percent for enteric products.
- Capsule shell integrity: visual and gravimetric assessment of softgel or hard capsule leakage, swelling, or rupture under acid conditions.
- Active ingredient retention: chemical assay of acid-sensitive actives after gastric simulation to quantify degradation losses.
- pH-dependent release characterization: release kinetics measured across a pH gradient from 1.2 to 7.5 to define the trigger point of the coating or matrix.
- Comparative survival analysis: side-by-side performance testing of competing formulations or successive prototypes.
Testing Methods
Simulated Gastric Fluid Preparation
The standard medium is prepared according to compendial formulas, most commonly the USP recipe: 2.0 g of sodium chloride and 7.0 mL of concentrated hydrochloric acid, diluted with purified water to 1000 mL, yielding a pH of approximately 1.2. For enzymatic simulation, 3.2 g of pepsin is added per liter. Enzyme-free SGF is used where pepsin would interfere with microbiological enumeration or specific analytical assays. Alternative test media at pH 2.0 or 3.0 with adjusted hydrochloric acid concentration may be used to represent typical rather than worst-case gastric conditions.
Static Acid Exposure and Probiotic Survival Testing
The product is introduced into pre-warmed SGF at 37 ± 0.5 °C with gentle agitation, simulating fasting gastric residence. Sampling is performed at defined intervals, commonly 0, 30, 60, 120, and 180 minutes. For probiotics, the acid reaction is neutralized at each time point, samples are serially diluted, and viable cells are enumerated by pour-plate or spread-plate methods on selective media under appropriate incubation atmospheres, following ISO 19344 or GB 4789.35 procedures. Survival is calculated as the log reduction relative to the initial count, and results are reported as log CFU per gram or per serving.
Disintegration Testing
Disintegration is performed in a pharmacopeial apparatus using SGF without discs for the acid stage, typically for one hour, during which the dosage form must show no evidence of disintegration or rupture. The medium is then replaced with simulated intestinal fluid or pH 6.8 phosphate buffer, and the test continues with discs until complete disintegration occurs, confirming that the formulation releases in the intestinal environment rather than the stomach.
Dissolution Testing
Two-stage dissolution is conducted in a validated paddle or basket apparatus at 37 ± 0.5 °C. The acid stage uses 0.1 N hydrochloric acid or SGF for two hours at 50 to 100 rpm, during which samples are withdrawn and assayed to verify that no more than a defined percentage of the active is released. The medium is then adjusted to pH 6.8 or replaced with intestinal buffer, and continued sampling generates a full release profile. Released actives are quantified by validated HPLC, UV-visible spectrophotometry, or other compendial assay methods.
Harmonized In Vitro Digestion Models
For a more physiologically comprehensive evaluation, laboratories may apply the standardized INFOGEST static digestion protocol, which subjects the product to sequential oral, gastric, and intestinal phases with defined enzymes, bile salts, pH values, and dwell times. This model is particularly useful for comparing formulations under realistic digestive conditions and for supporting bioaccessibility statements.
Typical Acceptance Criteria
- Enteric-coated products: no disintegration or rupture in acid medium for one hour; complete disintegration in intestinal buffer within 60 minutes; no more than 10 percent active release during the acid stage.
- Probiotic products: survival rate of at least 50 percent, or a log reduction of no more than 1.0 log CFU, after 2 hours at pH 3.0; higher-stringency products target less than 0.5 log reduction.
- Acid-labile actives: retention of the declared active content within product specification after simulated gastric exposure.
Applications
Gastric acid resistance testing serves multiple functions across the product lifecycle:
- Formulation development: comparing coating polymers, capsule shell materials, microencapsulation techniques, and protective matrices to identify the most acid-robust design.
- Quality control and batch release: verifying that routine production consistently meets acid resistance specifications defined in the product technical file.
- Claim substantiation: providing laboratory evidence for marketing statements such as acid-resistant, delayed-release, targeted intestinal release, or guaranteed survival through stomach acid.
- Regulatory compliance: supporting documentation requirements in markets where delivery-claim substantiation is expected, and aligning products with compendial performance criteria.
- Shelf-life and stability programs: confirming that acid resistance performance is maintained through the declared expiration date under ICH-aligned storage conditions.
- Competitive benchmarking: objectively comparing a product against reference formulations to demonstrate relative performance advantages.
- Ingredient supplier verification: validating that encapsulated or protected raw materials deliver the acid stability promised in supplier specifications.
FAQ
What pH and exposure time represent a worst-case gastric environment?
A pH of 1.2 to 2.0 for 2 hours approximates a worst-case fasting-state scenario. A pH of 3.0 for 2 to 3 hours is commonly used as a representative average condition. Testing at both levels provides a complete picture of product performance.
What survival rate is considered acceptable for probiotic products?
Industry practice generally treats a log reduction of 1.0 log CFU or less after 2 hours at pH 3.0 as acceptable acid tolerance, corresponding to at least 90 percent loss at the threshold. Premium formulations frequently target less than 0.5 log reduction. The relevant benchmark also depends on the total delivered dose and any minimum viable count guarantee at end of shelf life.
Is gastric acid resistance testing legally mandatory for supplements?
Requirements vary by market and product type. While routine acid tolerance testing is not universally mandated for all supplements, products bearing enteric, delayed-release, or survival claims are expected to hold substantiating data, and pharmacopeial performance criteria apply to delayed-release forms. Engaging accredited third-party laboratories ensures the data meet the evidentiary expectations of regulators and retailers.
How does this testing differ from ordinary disintegration testing?
Ordinary disintegration testing confirms that a dosage form breaks down within a set time in a single medium. Gastric acid resistance testing adds physiological specificity: an extended acid stage that the product must survive, followed by an intestinal stage that confirms release occurs only at the intended site, together with quantitative measurement of release or survival in each phase.
Can testing be performed directly on finished consumer products?
Yes. Testing finished products in their commercial form provides the most relevant evidence for claims, since coating quality, capsule sealing, and matrix behavior in the final dosage form can differ from those of prototype or bulk material. Testing should be repeated on samples held to the end of shelf life for full claim support.